DennisL.SprecherMD

Cardiology • Philadelphia, PA

Adult Congenital Heart Disease

Penn Heart and Vascular Center Perelman Center for Advanced Medicine

Join to view full profile

Dr. Sprecher is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sprecher's full profile

Already have an account?

Office
3400 Civic Center Blvd
# E
Philadelphia, PA 19104
Phone+1 215-615-4949

Fax+1 215-615-0829

Education & Training

Duke University HospitalFellowship, Cardiovascular Disease, 1985 - 1986
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1978 - 1980
Boston University School of MedicineClass of 1978

Certifications & Licensure

IL State Medical License 1979 - Present
PA State Medical License 2003 - 2024
OH State Medical License 1986 - 2020
MD State Medical License 1981 - 1993
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Lipid Research Clinics Coronary Primary Prevention Trial (CPPT) Start of enrollment: 1973 Jun 01
Completed
Phase 3

Publications & Presentations

PubMed

114 citations
Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.
L. Kristin Newby, Michael S. Marber, Chiara Melloni, Lea Sarov-Blat, Laura H. Aberle
Lancet. 2014-09-27
110 citations
Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.
Maysoon Elkhawad, James H.F. Rudd, Lea Sarov-Blat, Gengqian Cai, Richard J.B. Wells
JACC. Cardiovascular Imaging. 2012-09-01
121 citations
Circulating Fibroblast Growth Factor 21 Is Induced by Peroxisome Proliferator-Activated Receptor Agonists But Not Ketosis in Man
Constantinos Christodoulides, Pamela Dyson, Dennis L. Sprecher, Kostas Tsintzas, Fredrik Karpe
The Journal of Clinical Endocrinology and Metabolism. 2009-09-01

Press Mentions

Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients with Hereditary Hemorrhagic TelangiectasiaAugust 20th, 2018

Grant Support

APOB Kinetics In Heterozygous LPL DeficiencyNational Heart, Lung, And Blood Institute1994–1996
Genetic Epidemiology Of Sex Hormones And LipoproteinsEunice Kennedy Shriver National Institute Of Child Health &Human Development1991–1992
Support For Lipid Research ClinicDivision Of Heart And Vascular Diseases1987–1990